Back to Search Start Over

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

Authors :
Shadman, Mazyar
Ahn, Kwang W.
Kaur, Manmeet
Lekakis, Lazaros
Beitinjaneh, Amer
Iqbal, Madiha
Ahmed, Nausheen
Hill, Brian
Hossain, Nasheed M.
Riedell, Peter
Gopal, Ajay K.
Grover, Natalie
Frigault, Matthew
Brammer, Jonathan
Ghosh, Nilanjan
Merryman, Reid
Lazaryan, Aleksandr
Ram, Ron
Hertzberg, Mark
Savani, Bipin
Source :
Blood Cancer Journal; 7/8/2024, Vol. 14 Issue 1, p1-7, 7p
Publication Year :
2024

Abstract

In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24.7 months for the CAR-T cohort. Patients ages 18 and 75 with a diagnosis of DLBCL were included if they received auto-HCT (n = 281) or commercial CAR-T (n = 79) while in a CR. Patients undergoing auto-HCT with only one prior therapy line and CAR-T patients with a previous history of auto-HCT treatment were excluded. Endpoints included Progression-free survival (PFS), relapse rate, non-relapse mortality (NRM) and overall survival (OS). In univariate analysis, treatment with auto-HCT was associated with a higher rate of 2-year PFS (66.2% vs. 47.8%; p < 0.001), a lower 2-year cumulative incidence of relapse (27.8% vs. 48% ; p < 0.001), and a superior 2-year OS (78.9% vs. 65.6%; p = 0.037). In patients with early (within 12 months) treatment failure, auto-HCT was associated with a superior 2-year PFS (70.9% vs. 48.3% ; p < 0.001), lower 2-year cumulative incidence of relapse (22.8% vs. 45.9% ; p < 0.001) and trend for higher 2-year OS (82.4% vs. 66.1% ; p = 0.076). In the multivariable analysis, treatment with auto-HCT was associated with a superior PFS (hazard ratio 1.83; p = 0.0011) and lower incidence of relapse (hazard ratio 2.18; p < 0.0001) compared to CAR-T. In patients with relapsed LBCL who achieve a CR, treatment with auto-HCT is associated with improved clinical outcomes compared to CAR-T. These data support the consideration of auto-HCT in select patients with LBCL achieving a CR in the relapsed setting. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20445385
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
Blood Cancer Journal
Publication Type :
Academic Journal
Accession number :
178332983
Full Text :
https://doi.org/10.1038/s41408-024-01084-w